WHO Approves Emergency Use of Japanese Monkeypox Vaccine

The World Health Organization (WHO) has granted emergency use listing for Japan's LC16m8 mpox vaccine, marking a significant step in the global fight against the disease. This approval comes as a welcome development, particularly in light of the recent surge in mpox cases worldwide.

The LC16m8 vaccine, originally developed for smallpox, has been approved in Japan for use against mpox. The country applied for emergency use listing with the WHO, highlighting the vaccine's potential to contribute to global efforts to control the spread of the disease.

This approval marks the second emergency use listing for an mpox vaccine by the WHO. The organization previously granted emergency use listing for the Bavarian Nordic's Jynneos vaccine, which is also used to prevent smallpox.

The WHO's decision to grant emergency use listing for the LC16m8 vaccine is a testament to its potential effectiveness and safety. This approval will facilitate the vaccine's distribution to countries in need, particularly those experiencing outbreaks or at high risk of mpox transmission.

The availability of additional vaccines, such as the LC16m8 vaccine, is crucial in bolstering global efforts to combat mpox. This development underscores the importance of international collaboration and the role of organizations like the WHO in facilitating access to essential medical tools.